Idelalisib is a targeted therapy drug that plays an important role in the treatment of relapsed chronic lymphocytic leukemia (CLL). Patients and their families need to be fully aware of the purchase channels and medication specifications.
How to buy Idelalisib?
The purchase of Idelalisib should be made through formal medical channels, taking into account the patient's specific condition and doctor's advice.
Purchase channel and price information
Produced by Gilead in the United States, Idelalisib is available in 150mg×60 tablets. The drug is not yet marketed in China, is not covered by medical insurance, and is not generic. Patients need to be obtained through an import-qualified medical institution or international pharmacy. When purchasing, it is necessary to confirm that the drug packaging is complete, the bottle body is engraved with "GSI" and dosage identification (such as "150"), and check the production batch number and expiration date to avoid buying counterfeit or expired drugs.
Legal and medical advice before taking medication
Because the indication of Idelalisib is strictly limited to the second-line treatment of recurrent CLL, patients are required to provide a complete medical history and be evaluated by a hematologist before prescribing. Self-purchase of drugs for first-line treatment or other types of lymphoma is prohibited. Some countries may require a genetic test report or proof of treatment history, so it is recommended to consult the specific requirements of the target drug purchasing institution in advance.
When purchasing drugs across borders, you need to pay attention to customs policies, and some countries may restrict the quantity of drugs imported. It is recommended to entrust the assistance of a professional medical intermediary to ensure legal compliance.
Zydelig's method of preservation
Proper storage methods can maintain the pharmacodynamic stability of Idelalisib, and prevent the drug from becoming ineffective or deteriorating.
Storage conditions and packaging management
Idelalisib needs to be stored at 20°C-30°C, allowing for a brief shift to 15°C-30°C. Medicines should always be stored in their original bottles and should not be dispensed or transferred. If the seal is broken or the foil is missing, it should be discarded immediately. Make sure the cap is tightly closed after opening to prevent moisture or contamination.
Expiration date and shipping precautions
Unopened medicines have an expiration date of 24 months and need to be used within the expiration date stated on the package. High temperatures, freezing, or severe shaking should be avoided during transportation. For international shipments, it is recommended to use temperature-controlled logistics to ensure that the temperature is stable between 15°C-30°C. If the drug is exposed to extreme environments during transportation, it is necessary to contact the supplier for quality testing before use.
Patients should check the properties of the drug regularly, stop taking the tablets if they have discoloration, cracks or odors, and contact the doctor in time to change the batch.
The target of action of Idelalisib
By specifically inhibiting PI3Kδ kinase, Idelalisib exerts anti-tumor effects by blocking the survival signaling pathway of malignant B cells.
PI3Kδ inhibition mechanism and efficacy
PI3Kδ kinase plays a central role in B cell receptor signaling. By selectively inhibiting the enzyme, Idelalisib reduces the activation of the AKT/mTOR pathway and induces apoptosis in tumor cells. Clinical studies have shown that the combination with rituximab can significantly prolong the progression-free survival of patients with relapsed CLL, and the objective response rate is increased to 82%.
Indication restriction and combination medication specifications
Idelalisib is only approved in combination with rituximab for the second-line treatment of relapsed CLL and is not indicated for other indications such as follicular lymphoma. Concomitant with bendamustine is contraindicated to avoid increasing the risk of hepatotoxicity. During treatment, liver function (ALT/AST), neutrophil count, and infection indicators should be monitored regularly, and the dose should be adjusted or the drug should be discontinued.
The metabolism of Idelalisib is dependent on the CYP3A enzyme, and when combined with a strong CYP3A inhibitor (eg, ketoconazole) or an inducer (eg, rifampicin), it may affect plasma levels and should be adjusted under the guidance of a physician.
Proper use of Idelalisib requires strict adherence to the doctor's instructions, regular check-ups and recording of adverse reactions. If you have persistent diarrhea, difficulty breathing, or a worsening rash during treatment, you should seek medical attention immediately. Families need to help manage the timing and storage conditions of medication to ensure continuity of treatment.
